Digital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Our content is fact checked by our senior editorial staff to reflect accuracy and ensure our readers get sound information and advice to make the smartest, healthiest choices.
Interestingly enough, when looking at health insurance claims from 16 million non-diabetic patients in the U.S. on GLP-1s, researchers found that they, too, are at risk for the following three rare and severe stomach conditions., affects the nerves and muscles in the stomach, slowing and weakening muscle contractions needed to digest and pass food through the intestines, according to the Cleveland Clinic.
The higher risk was determined by comparing patients taking GLP-1s to those taking bupropion-naltrexone, another weight loss treatment that goes by the brand name. Per the study data and CNBC, those on GLP-1s had a three times higher risk of stomach paralysis than those on bupropion-naltrexone.Patients taking GLP-1s for weight loss also had an increased risk of bowel obstruction, study data suggests.
"We're all big proponents for informed patient consent," Sodhi told CNBC."If someone has decided they would like to take a GLP-1 for weight loss, we encourage them to have a conversation with their provider about how it may help them achieve their goals. But they should also be made aware of the potential drawbacks of taking this medication."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight Loss Drugs Ozempic and Wegovy Linked to Severe Gut Problems: StudyA small percentage of users may experience severe gastrointestinal side effects.
Read more »
Ozempic, Wegovy linked to severe medical conditions including stomach problems, study findsBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Ozempic and Wegovy linked to gastrointestinal problems in new researchGabrielle M. Etzel is the healthcare policy reporter for the Washington Examiner. Prior to joining the Washington Examiner, she served as a staff reporter at Campus Reform and as a freelance writer. After graduating from Grove City College, Etzel earned her master's in public policy and administration from Baylor University, where she conducted research on domestic sex trafficking. In her free time, Etzel enjoys being with her family in Pittsburgh, Pennsylvania.
Read more »
Wegovy and Ozempic ingredient linked to rare stomach paralysis casesA study involving 16 million people in the US found that those prescribed so-called GLP-1-agonists had an increased risk of serious gastrointestinal conditions, including stomach paralysis
Read more »
New Ozempic and Wegovy side effects come to lightThis is additional taxonomy that helps us with analytics
Read more »